Weight-Loss Drugs Among the Most Sought-After New Corporate Benefits

The Mercer survey was conducted before Eli Lilly & Co. won US clearance this week for Zepbound, a version of its diabetes drug Mounjaro that will be specifically marketed to patients with obesity in coming weeks. Both drugs belong to a class of medicines known as GLP-1 receptor agonists. The group also includes Novo Nordisk A/S’s Wegovy, which is approved for obesity, and Ozempic, a diabetes drug that is often used for weight loss. List prices for the drugs range from $936 per month to nearly $1,350.

Leave a Comment